Skip to main content
Study examines efficacy, safety of dapagliflozin in diabetes

Researchers evaluated 833 patients with inadequately controlled type 1 diabetes and found an adjusted mean change in A1C level of -0.27% among those who received 5 mg of dapagliflozin for 52 weeks, compared with -0.31% in the 10-mg dapagliflozin group and -0.06% in the placebo group. The findings in Diabetes Care revealed those in the 5-mg dapagliflozin group lost an average of 2.95% more body weight than the placebo group, while the 10-mg dapagliflozin group lost 4.54% more.

Full Story: